Faster access to innovative medicines has prevented 1.8 million lost life years across Europe from 2014 to 2022, reports EFPIA.
However, access varies drastically: German patients wait an average of 56 days after approval, while Romanian patients face delays of up to three years. Stefan Oelrich of EFPIA emphasizes the need for Europe to foster an environment for rapid patient access to scientific advancements.
The report highlights that timely access to new therapies can lessen healthcare system strain, with innovative medicines reducing hospital stays by 20.9 million days in 29 countries. Additionally, the investment in these medicines yields an economic impact exceeding €66bn.
Nathalie Moll from EFPIA underscores the importance of healthcare investment for societal benefit, warning that neglecting health budgets is a politically damaging decision. The findings raise questions about Europe’s position in the global life sciences sector, where spending on pharmaceuticals is lower than in the US and China.